Taku Yoshiya

Dr. Taku Yoshiya

Peptide Institute
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Vasso ApostolopoulosVasso Apostolopoulos
Vasso Apostolopoulos
BJBojarska Joanna
Bojarska Joanna
Tsun-Thai ChaiTsun-Thai Chai
Tsun-Thai Chai
Sherif M. ElnagdySherif M. Elnagdy
Sherif M. Elnagdy
KKKrzysztof Kaczmarek
Krzysztof Kaczmarek
Istvan TothIstvan Toth
Istvan Toth
Peptides are fragments of proteins that carry out biological functions. They act as signaling entities via all domains of life and interfere with protein-protein interactions, which are indispensable in bio-processes. Short peptides include fundamental molecular information for a prelude to the symphony of life. They have aroused considerable interest due to their unique features and great promise in innovative bio-therapies. This work focusing on the current state-of-the-art short peptide-based therapeutical developments is the first global review written by researchers from all continents, as a celebration of 100 years of peptide therapeutics since the commencement of insulin therapy in the 1920s. Peptide “drugs” initially played only the role of hormone analogs to balance disorders. Nowadays, they achieve numerous biomedical tasks, can cross membranes, or reach intracellular targets. The role of peptides in bio-processes can hardly be mimicked by other chemical substances. The article is divided into independent sections, which are related to either the progress in short peptide-based theranostics or the problems posing challenge to bio-medicine. In particular, the SWOT analysis of short peptides, their relevance in therapies of diverse diseases, improvements in (bio)synthesis platforms, advanced nano-supramolecular technologies, aptamers, altered peptide ligands and in silico methodologies to overcome peptide limitations, modern smart bio-functional materials, vaccines, and drug/gene-targeted delivery systems are discussed.

18 January 2007 in Peptide Science
Verified
Journal Article
Open access
PDF file
YSYouhei Sohma
Youhei Sohma
TYTaku Yoshiya
Taku Yoshiya
ATAtsuhiko Taniguchi
Atsuhiko Taniguchi
TKTooru Kimura
Tooru Kimura
YHYoshio Hayashi
Yoshio Hayashi
YKYoshiaki Kiso
Yoshiaki Kiso
During over a decade of study on aspartic protease inhibitors and water‐soluble prodrugs, in 2003, we discovered that the presence of an O‐acyl instead of N‐acyl residue within the peptide backbone significantly changed the secondary structure of the native peptide. In addition, the target peptide was subsequently generated by an O‐N intramolecular acyl migration reaction. These findings led to the development of a novel method, called “O‐acyl isopeptide method,” for the synthesis of peptides containing difficult sequence. Further application of the method to Alzheimer's Aβ1‐42 revealed that the O‐acyl isopeptide of Aβ1‐42 could be effectively synthesized and stored without spontaneous self‐assembly. Intact monomer Aβ1‐42 could then be obtained from the isopeptide under physiological experimental conditions. We named the O‐acyl isopeptide as “Click Peptide,” because of its “quick and easy one‐way conversion” to the parent Aβ1‐ 42. Application of the click peptide has provided a new basis for the investigation of the biological functions of Aβ1‐42 by inducible activation of its self‐assembly. The O‐acyl isopeptide method has further evolved as a general method for peptides synthesis with our recent developments of “O‐acyl isodipeptide units” and “racemization‐free segment condensation methodology.” Isodipeptide units have enabled routine use of the O‐acyl isopeptide method by avoiding the often difficult esterification reaction on resin. “Racemizationfree segment condensation methodology” has been achieved by employing N‐segments possessing a C‐terminal urethaneprotected O‐acyl Ser/Thr residues. The synthesis of long peptides/proteins by racemization‐free segment condensation has thus become possible at Ser/Thr residues instead of Cterminal Gly/Pro residues. As the O‐acyl isopeptide method becomes more widely utilized, we have composed this review to facilitate its application for the production of peptides and proteins. © 2007 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 88: 253–262, 2007.This article was originally published online as an accepted preprint. The ‘Published Online’ date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at biopolymers@wiley.com

26 February 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
TMTakafumi Minato
Takafumi Minato
SNSatoru Nirasawa
Satoru Nirasawa
TSTeruki Sato
Teruki Sato
TYTomokazu Yamaguchi
Tomokazu Yamaguchi
MHMidori Hoshizaki
Midori Hoshizaki
KKKeiji Kuba
Keiji Kuba
Angiotensin-converting enzyme 2 (ACE2) is critically involved in cardiovascular physiology and pathology, and is currently clinically evaluated to treat acute lung failure. Here we show that the B38-CAP, a carboxypeptidase derived from Paenibacillus sp. B38, is an ACE2-like enzyme to decrease angiotensin II levels in mice. In protein 3D structure analysis, B38-CAP homolog shares structural similarity to mammalian ACE2 with low sequence identity. In vitro, recombinant B38-CAP protein catalyzed the conversion of angiotensin II to angiotensin 1–7, as well as other known ACE2 target peptides. Treatment with B38-CAP suppressed angiotensin II-induced hypertension, cardiac hypertrophy, and fibrosis in mice. Moreover, B38-CAP inhibited pressure overload-induced pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction in mice. Our data identify the bacterial B38-CAP as an ACE2-like carboxypeptidase, indicating that evolution has shaped a bacterial carboxypeptidase to a human ACE2-like enzyme. Bacterial engineering could be utilized to design improved protein drugs for hypertension and heart failure.

25 January 2018 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
STShugo Tsuda
Shugo Tsuda
MMMasayoshi Mochizuki
Masayoshi Mochizuki
HIHiroyuki Ishiba
Hiroyuki Ishiba
KYKumiko Yoshizawa‐Kumagaye
Kumiko Yoshizawa‐Kumagaye
HNHideki Nishio
Hideki Nishio
TYTaku Yoshiya
Taku Yoshiya

1 May 2006 in Tetrahedron Letters
Verified
Journal Article
Closed access
YSYouhei Sohma
Youhei Sohma
ATAtsuhiko Taniguchi
Atsuhiko Taniguchi
Mariusz SkwarczynskiMariusz Skwarczynski
Mariusz Skwarczynski
TYTaku Yoshiya
Taku Yoshiya
FFFukue Fukao
Fukue Fukao
YKYoshiaki Kiso
Yoshiaki Kiso

Verified
Journal Article
Open access
PDF file
SKSusumu Kageyama
Susumu Kageyama
HIHiromi Ii
Hiromi Ii
KTKeiko Taniguchi
Keiko Taniguchi
SKShigehisa Kubota
Shigehisa Kubota
TYTetsuya Yoshida
Tetsuya Yoshida
SNSusumu Nakata
Susumu Nakata
γ-Glutamylcyclotransferase (GGCT), which is one of the major enzymes involved in glutathione metabolism, is upregulated in a wide range of cancers—glioma, breast, lung, esophageal, gastric, colorectal, urinary bladder, prostate, cervical, ovarian cancers and osteosarcoma—and promotes cancer progression; its depletion leads to the suppression of proliferation, invasion, and migration of cancer cells. It has been demonstrated that the suppression or inhibition of GGCT has an antitumor effect in cancer-bearing xenograft mice. Based on these observations, GGCT is now recognized as a promising therapeutic target in various cancers. This review summarizes recent advances on the mechanisms of the antitumor activity of GGCT inhibition.